<DOC>
	<DOCNO>NCT00561470</DOCNO>
	<brief_summary>The main objective study evaluate effectiveness aflibercept ( versus placebo ) increase overall survival participant metastatic colorectal cancer treat FOLFIRI ( Irinotecan , 5-Fluorouracil , Leucovorin ) previously fail oxaliplatin base treatment metastatic disease . The secondary objective compare progression-free survival , evaluate overall response rate , evaluate safety profile , assess immunogenicity intravenous ( IV ) aflibercept , assess pharmacokinetics IV aflibercept treatment arm .</brief_summary>
	<brief_title>Aflibercept Versus Placebo Combination With Irinotecan 5-FU Treatment Patients With Metastatic Colorectal Cancer After Failure Oxaliplatin Based Regimen</brief_title>
	<detailed_description>Participants - randomize baseline ( treatment initiate 3 day randomization ) - administer treatment cycle 14-days till study withdrawal criterion meet - follow 30 day discontinuation treatment , every 8 week death end study . The criterion discontinuation study treatment participant : - participant ( legal representative ) choose withdraw treatment - investigator think continuation study would detrimental participant well-being due - disease progression - unacceptable AEs - intercurrent illnesses - non-compliance study protocol - participant lose follow-up - participant unblinded investigational treatment</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Participants meet follow main selection criterion include study . Histologically cytologically proven adenocarcinoma colon rectum Metastatic disease amenable potentially curative treatment One one prior line treatment metastatic disease . This prior line oxaliplatin base chemotherapy ( participant relapse within 6 month completion oxaliplatin base adjuvant chemotherapy eligible ) Prior treatment bevacizumab permit . Prior therapy irinotecan Eastern Cooperative Oncology Group performance status &gt; 2 The information intend contain consideration relevant participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>anti-angiogenic</keyword>
	<keyword>irinotecan</keyword>
	<keyword>5-FU</keyword>
	<keyword>FOLFIRI</keyword>
</DOC>